{"product_id":"kenvue-bcg-matrix","title":"Kenvue Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious where Kenvue’s products sit — Stars, Cash Cows, Dogs or Question Marks? This snapshot hints at positioning, but the full BCG Matrix gives quadrant-by-quadrant clarity, data-backed recommendations, and a ready-to-use strategy. Purchase the complete report to cut through the noise and start making smarter investment and product decisions today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eListerine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eListerine sits in a growing global mouthwash market estimated at about $6.7 billion in 2024 with a ~5% CAGR as premiumization and rinse adoption rise in emerging markets. Listerine offers category leadership with a ≈35% global share and strong dental professional endorsements. Maintain heavy media, sampling and dentist partnerships to defend share while the market expands. Rapidly scale innovations in gum health and sensitivity to capture premium growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeutrogena\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeutrogena is a Stars asset for Kenvue, delivering roughly 20% of Kenvue’s 2024 net sales—about $2.7B of ~$13.5B—driven by derm‑backed facial care, sun protection and derm‑beauty crossovers. The brand holds high share in key mass and drug channels with a strong science narrative and clinical claims that support premium pricing. Prioritize investment in hero SKUs, clinical studies and DTC content to convert younger shoppers. Win in retail endcaps and social‑led launch cycles to sustain growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAveeno\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAveeno, Kenvue’s sensitive-skin authority, benefits from the skin-barrier and natural-leaning trends and shows strong momentum in eczema relief and gentle body care. Maintain elevated R\u0026amp;D and HCP advocacy while expanding into derm-problem and OTC-adjacent sets. Prioritize refillable formats and credible eco cues only where retail velocity proves impact. Leverage clinical positioning to defend premium pricing and channel growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZyrtec\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZyrtec remains a Stars-position brand for Kenvue: allergy is a resilient, seasonally spiky category and Zyrtec's multi-decade recognition drives high repeat usage and strong retail velocity; 2024 retail sales exceeded $1B globally, supporting continued investment in always-on retail presence and weather-triggered digital peaks.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMaintain always-on retail distribution\u003c\/li\u003e\n\u003cli\u003eDeploy weather-triggered digital media\u003c\/li\u003e\n\u003cli\u003eSelective line-extensions: kids, dissolvables\u003c\/li\u003e\n\u003cli\u003eDefend versus flankers via premium SKUs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTear-free Baby Cleansing (Johnson’s)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTear-free Baby Cleansing (Johnson’s) is a Stars BCG position as the baby wash\/shampoo line is regaining trust through gentler, simpler formulas and expanded parent education efforts in 2024, with momentum in select markets and online gifting kits driving share gains. Focus: double down on pediatrician endorsements and subscription bundles while localizing fragrances and formats without overcomplicating SKUs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePediatrician endorsements—priority\u003c\/li\u003e\n\u003cli\u003eSubscription bundles + gifting kits—scale online\u003c\/li\u003e\n\u003cli\u003eLocalized fragrances\/formats—limit SKU complexity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral-care crowns a \u003cstrong\u003e$6.7B\u003c\/strong\u003e market as skin and allergy lines reach billion-dollar scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Listerine leads a $6.7B mouthwash market (2024) at ≈35% share; Neutrogena ~ $2.7B (≈20% of Kenvue’s $13.5B 2024 sales); Aveeno strong in sensitive skin\/eczema; Zyrtec \u0026gt;$1B retail sales (2024); Johnson’s baby wash regaining share via pediatric endorsements.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eListerine\u003c\/td\u003e\n\u003ctd\u003e$6.7B market, ≈35% share\u003c\/td\u003e\n\u003ctd\u003ePremiumization, 5% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeutrogena\u003c\/td\u003e\n\u003ctd\u003e$2.7B\u003c\/td\u003e\n\u003ctd\u003e20% of Kenvue sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZyrtec\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1B\u003c\/td\u003e\n\u003ctd\u003eSeasonal peaks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIn-depth BCG review of Kenvue products with strategic moves for Stars, Cash Cows, Question Marks and Dogs - invest, hold or divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eClean, distraction-free Kenvue BCG Matrix condenses portfolios into one-page quadrants for swift C‑level decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTylenol\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTylenol sits as a classic cash cow: core analgesic with massive household penetration in a mature category, delivering reliable velocity, strong gross margins and low relative promotional need. Protecting shelf space and flawless supply are priority operational levers; keep dosing education clear to sustain trust and reduce liability. Milk steady cash flows and trial premium packs only in markets where observed price elasticity supports uppricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMotrin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMotrin is an established ibuprofen franchise dating to 1974 with strong repeat purchasers and high brand trust, positioned as a cash cow within Kenvue’s pain portfolio. Category growth is modest, supporting steady cash flow while efficient trade spend and clear OTC claims limit private-label erosion. Focus on pack-size optimization and club-format SKUs to boost gross margins and working-capital conversion in core markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBand-Aid\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBand-Aid, owned by Kenvue (the consumer-health company spun out of Johnson \u0026amp; Johnson in 2023), is an iconic first-aid leader in a stable, habitual market. High brand default at shelf and wide distribution support steady cash flow; refresh designs and kid licenses sparingly to sustain relevance. Use Kenvue's scale to secure premium placement and minimize promotional depth to protect margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeosporin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNeosporin, under Kenvue (spun off from Johnson \u0026amp; Johnson in 2023), functions as a Cash Cow: antibiotic ointments see steady, need-driven purchases with low innovation burden and durable brand recall, enabling stable OTC margins and predictable cash generation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKeep education simple: wound healing steps\u003c\/li\u003e\n\u003cli\u003ePromote combo value packs\u003c\/li\u003e\n\u003cli\u003eDifferentiate vs store brands with clear functional claims\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLip \u0026amp; Body Lotions (core lines)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLip and body lotions (core lines) are mature body-care staples for Kenvue, delivering consistent unit turns and predictable seasonal patterns that support stable cash generation.\u003c\/p\u003e\n\u003cp\u003eThese SKUs are margin-friendly when sourced and packed efficiently, so priority is on supply-chain optimization and mix management rather than heavy media spending.\u003c\/p\u003e\n\u003cp\u003eUse seasonal multi-packs and bundle promotions to smooth demand peaks and reduce stockouts, preserving shelf velocity and unit economics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: supply-chain \u0026amp; mix management\u003c\/li\u003e\n\u003cli\u003eChannel: low-media, trade\/promotions\u003c\/li\u003e\n\u003cli\u003eTactic: seasonal multi-packs to smooth demand\u003c\/li\u003e\n\u003cli\u003eBenefit: predictable turns, margin resilience\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDefend OTC margins: shelf, supply and pack\/mix protect cash-cow profits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTylenol, Motrin, Band‑Aid and Neosporin are Kenvue cash cows delivering steady OTC cash flow with low promo intensity and high household penetration; prioritize shelf, supply and pack\/mix to protect margins. 2024 saw Kenvue net sales of 12.9 billion USD, with cash‑cow categories contributing ~60% of OTC operating profit; focus on margin-preserving SKUs and seasonal bundles.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKenvue net sales\u003c\/td\u003e\n\u003ctd\u003e12.9B USD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash-cow OP contribution\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eKenvue BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe Kenvue BCG Matrix you're previewing is the exact file you'll receive after purchase. No watermarks, no placeholder content—just a fully formatted, ready-to-use strategic report. Designed by strategy experts, it's editable and presentation-ready for your team or investors. Buy once and download immediately; what you see is precisely what lands in your inbox.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClean \u0026amp; Clear\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClean \u0026amp; Clear, a legacy teen acne brand from the J\u0026amp;J lineage now in Kenvue, is being squeezed by derm-clinic labels and fast-growing indie players; it holds low share in core U.S. and EU teen skincare segments. Industry data shows acne treatment\/category growth is modest, ~4% CAGR (2024–29), limiting upside for heavy investment. With slow-to-no growth in key markets and constrained ROI, pruning SKUs or licensing the brand out warrants serious consideration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-tail Regional OTC SKUs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLong-tail regional OTC SKUs—niche pain\/cold remedies with limited geography and weak awareness—often follow an 80\/20 pattern: roughly 30% of SKUs can contribute under 5% of sales, while tying up working capital and incurring shelf fees with little pull. Rationalize or exit non-velocity codes, retaining only top-performing SKUs to improve turns. Reallocating inventory spend toward digital-first winners can unlock cash and margin to fund growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOlder Baby Accessories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOlder Baby Accessories sit in Dogs: non-core combs, kits and gadgets deliver low margin with little brand leverage and face a fragmented, commoditized market where private-label penetration exceeds 30% in key markets (2024). Trim the tail, redirect R\u0026amp;D and shelf space to wash and skin care where Kenvue brand equity drives premium placement and higher margins. Pursue divestment if credible buyers emerge to reallocate capital to core growth segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Mouth Fresheners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDogs: Legacy Mouth Fresheners sit as low-growth, low-share sideline in Kenvue’s oral-care portfolio; the global oral-care market was about $44.9B in 2024, but mouth-freshener subsegments show low single-digit growth and limited differentiation. Private-label penetration (~10% in US oral care) keeps price pressure high, so sunset quietly and reallocate capex and marketing to therapeutic rinses; avoid distraction.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCategory: Dogs\u003c\/li\u003e\n\u003cli\u003eMarket size: $44.9B (2024)\u003c\/li\u003e\n\u003cli\u003ePrivate-label pressure: ~10%\u003c\/li\u003e\n\u003cli\u003eAction: Sunset, reallocate to therapeutics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnderperforming Sun Sub-lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUnderperforming Sun sub-lines sit in the Dogs quadrant after 2024 saw new-launch momentum shift to mineral and dermatologist-led formats, leaving legacy SPF formats with declining velocity and rising inventory days. Shelf presence without consumer pull has become a cash trap; delist laggards and concentrate on hero SKUs that sustain proven sell-through. Recycle weak claims into stronger franchises focused on mineral, sensitive-skin and dermatologist-endorsed positioning.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eAction: delist slow SKUs; retain top-velocity heroes\u003c\/li\u003e\n\u003cli\u003eInventory: cut shelf-facing SKUs to reduce cash drag\u003c\/li\u003e\n\u003cli\u003eClaim recycle: repackage claims into mineral\/derm-led franchises\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrune legacy SKUs, reallocate to derm-led and mineral sun winners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: low-share, low-growth legacy SKUs (Clean \u0026amp; Clear teen acne, older baby accessories, mouth fresheners, underperforming sun lines) tie up inventory and margin; core markets show ~4% acne CAGR (2024–29) and global oral-care $44.9B (2024) with ~10% private-label pressure. Prune tails, license or divest, reallocate capex\/marketing to high-velocity derm-led and sun mineral heroes.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003e2024 Market\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003cth\u003eAction\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcne (Clean \u0026amp; Clear)\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003e~4% CAGR\u003c\/td\u003e\n\u003ctd\u003eLicense\/prune\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral: mouth fresheners\u003c\/td\u003e\n\u003ctd\u003e$44.9B\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003eLow single digits\u003c\/td\u003e\n\u003ctd\u003eSunset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDerm Sunscreen Revamps\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDerm Sunscreen Revamps sit in high-growth sun care pockets — mineral SPF segment grew ~12% in 2024 and daily\/sensitive subsegments outpaced category averages — yet these niches are crowded with legacy and indie rivals, leaving Kenvue with low share in some retail and digital channels. Heavy investment in claim validation and UGC-driven social proof can rapidly convert trial into share; if early KPIs (trial, repeat) lag after 6–9 months, cut fast to reallocate spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral Care Devices \u0026amp; Advanced Rinses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOral Care Devices \u0026amp; Advanced Rinses sit as Question Marks: the global mouthwash market is about $7B in 2024 and electric toothbrushes near $4B, with Listerine holding roughly 30% share in many markets, showing adjacency and tech-led whitening\/gum-health upsides. Category growth is real but share is not guaranteed; success requires dentist endorsement, consumer education and disciplined premium pricing. Pilot big in key test markets, then scale rapidly or shelve.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWomen’s Intimate \u0026amp; pH-care Expansions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising consumer demand for gentle, OB-GYN‑recommended pH‑balanced routines is driving a sector growing at an estimated 5–7% CAGR through 2028 (2024 market reports), yet Kenvue—with roughly $13.4bn in 2023 consumer health revenue—still holds limited share in intimate\/pH care subsegments. Rapid rollout of clinical claims, published trials and retail education are required to convert trial into share. Kenvue should invest aggressively or form strategic partnerships rather than test-the-waters. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSleep \u0026amp; Stress OTC Adjacent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSleep \u0026amp; Stress OTC Adjacent sits as a Question Mark: consumer demand for sleep and stress relief surged post‑pandemic with WHO and national surveys showing persistent sleep deficits, but brand permission must be earned through clinical credibility. Early pilots can burn cash before traction; if concept tests clear, prioritize clear safety and dosing guidance and robust adverse‑event monitoring. If not scalable, prefer licensing or divestment to protect margins and R\u0026amp;D runway.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket signal: sustained consumer interest in sleep\/stress remedies\u003c\/li\u003e\n\u003cli\u003eRisk: high pilot burn with uncertain repeat purchase\u003c\/li\u003e\n\u003cli\u003eGo\/no‑go: proceed only after positive concept and safety data\u003c\/li\u003e\n\u003cli\u003eExit: license or walk if metrics fail\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBaby Naturals \u0026amp; Subscription Bundles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eQuestion Marks: Baby Naturals \u0026amp; Subscription Bundles face fierce online competition despite parents prioritizing clean formulas and predictable replenishment; 2024 e-commerce penetration in baby care is ~30%, share is patchy and loyalty fragile. Differentiate via pediatrician-led content and skin science; if projected LTV fails sensitivity tests, plan a rapid exit.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrioritize pediatrician-led content\u003c\/li\u003e\n\u003cli\u003eMeasure LTV\/CAC monthly\u003c\/li\u003e\n\u003cli\u003eExit if LTV \u0026lt; 1.2 within 12 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNiche plays: derm +\u003cstrong\u003e12%\u003c\/strong\u003e, oral \u003cstrong\u003e$4B\u003c\/strong\u003e\/\u003cstrong\u003e$7B\u003c\/strong\u003e, test trial→repeat\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks: Derm sunscreen niches grew ~12% in 2024 but Kenvue holds low share; oral care devices\/mouthwash markets ~$4B\/$7B (2024) with Listerine ~30% share; baby naturals e‑commerce ~30% penetration (2024) and Kenvue share patchy; sleep\/stress pilots need safety proof before scale. Measure trial, repeat, LTV\/CAC; scale fast or exit.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 market\u003c\/th\u003e\n\u003cth\u003eKenvue share\u003c\/th\u003e\n\u003cth\u003eKey KPI\u003c\/th\u003e\n\u003cth\u003eGo\/no‑go\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDerm sunscreen\u003c\/td\u003e\n\u003ctd\u003emineral +12% growth\u003c\/td\u003e\n\u003ctd\u003elow\u003c\/td\u003e\n\u003ctd\u003etrial→repeat\u003c\/td\u003e\n\u003ctd\u003e6–9m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral care\u003c\/td\u003e\n\u003ctd\u003e$4B\/$7B\u003c\/td\u003e\n\u003ctd\u003eadjacent\u003c\/td\u003e\n\u003ctd\u003edentist uptake\u003c\/td\u003e\n\u003ctd\u003epilot→scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBaby naturals\u003c\/td\u003e\n\u003ctd\u003ee‑comm 30%\u003c\/td\u003e\n\u003ctd\u003epatchy\u003c\/td\u003e\n\u003ctd\u003eLTV\/CAC\u003c\/td\u003e\n\u003ctd\u003eexit if LTV\u0026lt;1.2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSleep\/stress\u003c\/td\u003e\n\u003ctd\u003egrowing post‑pandemic\u003c\/td\u003e\n\u003ctd\u003enone\/limited\u003c\/td\u003e\n\u003ctd\u003esafety trials\u003c\/td\u003e\n\u003ctd\u003elicense if fail\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098379915612,"sku":"kenvue-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/kenvue-bcg-matrix.png?v=1781798724","url":"https:\/\/pestel-analysis.com\/products\/kenvue-bcg-matrix","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}